pregnant or breast feeding, due to potential teratogenicity hepatic impairment - (ast or alt > 3.5 x upper limit of normal) presently enrolled in an interventional drug study unable to take medication via the oral or nasogastric route known sensitivity favipiravir

pregnant or breast feeding, due to potential teratogenicity hepatic impairment - (ast or alt > 3.5 x upper limit of normal) presently enrolled in an interventional drug study unable to take medication via the oral or nasogastric route known sensitivity favipiravir

1. pregnant or breast feeding, due to potential teratogenicity 2. hepatic impairment - (ast or alt > 3.5 x upper limit of normal) 3. presently enrolled in an interventional drug study 4. unable to take medication via the oral or nasogastric route 5. known sensitivity favipiravir

1. pregnant or breast feeding, due to potential teratogenicity 2. hepatic impairment - (ast or alt > 3.5 x upper limit of normal) 3. presently enrolled in an interventional drug study 4. unable to take medication via the oral or nasogastric route 5. known sensitivity favipiravir

1. pregnant or breast feeding, due to potential teratogenicity 2. hepatic impairment - (ast or alt > 3.5 x upper limit of normal) 3. renal impairment - (egfr <10ml/ minute) 4. known history of retinopathy 5. known history of g6pd deficiency 6. known history of myasthenia gravis 7. qt-prolongation (>450ms in males or >470ms in females, calculated as per investigators discretion) 8. presently enrolled in an interventional drug study or on hydroxychloroquine or azithromycin for other therapeutic reasons 9. unable to take medication via the oral or nasogastric route 10. immunocompromised patients (see appendix c) 11. known sensitivity to favipiravir

1. pregnant or breast feeding, due to potential teratogenicity 2. hepatic impairment - (ast or alt > 3.5 x upper limit of normal) 3. renal impairment - (egfr <10ml/ minute) 4. known history of retinopathy 5. known history of g6pd deficiency 6. known history of myasthenia gravis 7. qt-prolongation (>450ms in males or >470ms in females, calculated as per investigators discretion) 8. presently enrolled in an interventional drug study or on hydroxychloroquine or azithromycin for other therapeutic reasons 9. unable to take medication via the oral or nasogastric route 10. immunocompromised patients (see appendix c) 11. known sensitivity to favipiravir